Proceedings of the National Academy of Sciences · 2021 · 42 citations · 27 references
PharmacyMedicinal ChemistryOncologyCancer PharmacologyDrug DiscoveryMolecular OncologyAntibody ConjugatesAntibody ConjugationAntibody-drug ConjugatesCancer ImmunotherapyTargeted Cancer TherapyTargeted TherapyAntibody - Enzyme ConjugatesAntibody-directed ProdrugsAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyAntibody-enzyme ConjugatesDrug-protein ConjugatesEnediyne AntibioticsPhase I Clinical Trials
-acetyl calicheamicin [Formula: see text], have a proven success track record. However, they pose a significant synthetic challenge in the development and optimization of linker drugs. We have recently reported a streamlined total synthesis of uncialamycin, another representative of the enediyne class of compounds, with compelling synthetic accessibility. Here we report the synthesis and evaluation of uncialamycin ADCs featuring a variety of cleavable and noncleavable linkers. We have discovered that uncialamycin ADCs display a strong bystander killing effect and are highly selective and cytotoxic in vitro and in vivo.
27
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +13